Rhythm Pharmaceuticals Reports Strong Preliminary 2025 IMCIVREE Revenue

Rhythm Pharmaceuticals ( (RYTM) ) has shared an announcement.

On January 9, 2026, Rhythm Pharmaceuticals reported preliminary, unaudited net product revenues from global sales of IMCIVREE of about $57 million for the fourth quarter of 2025, up 11% sequentially from the third quarter, and approximately $194 million for full-year 2025, a roughly 50% increase over 2024, with U.S. sales accounting for about two-thirds of the total; the company plans to release final fourth-quarter and full-year results in late February 2026. Rhythm also outlined a packed 2026 clinical and regulatory agenda centered on expanding setmelanotide into acquired and congenital hypothalamic obesity and genetically caused MC4R pathway diseases, advancing programs in Prader-Willi syndrome, and progressing its oral MC4R agonist bivamelagon and next-generation candidate RM-718, underscoring its bid to deepen its rare obesity franchise and sustain growth, although all financial figures remain preliminary and unaudited.

The most recent analyst rating on (RYTM) stock is a Buy with a $129.00 price target. To see the full list of analyst forecasts on Rhythm Pharmaceuticals stock, see the RYTM Stock Forecast page.

Spark’s Take on RYTM Stock

According to Spark, TipRanks’ AI Analyst, RYTM is a Neutral.

Rhythm Pharmaceuticals’ overall stock score is driven by strong technical indicators and positive corporate events, such as promising trial results and regulatory progress. However, financial performance and valuation remain weak due to ongoing profitability challenges and a negative P/E ratio. The earnings call provided a positive sentiment, highlighting revenue growth and strategic initiatives, which slightly offset the financial weaknesses.

To see Spark’s full report on RYTM stock, click here.

More about Rhythm Pharmaceuticals

Rhythm Pharmaceuticals is a Boston-based commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases. Its lead product, IMCIVREE (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved in the U.S., European Union and United Kingdom for certain forms of syndromic and monogenic obesity, including Bardet-Biedl syndrome and genetically confirmed POMC, PCSK1 and LEPR deficiencies. The company is also developing additional MC4R agonists, bivamelagon and RM-718, along with a preclinical portfolio targeting congenital hyperinsulinism.

Average Trading Volume: 771,314

Technical Sentiment Signal: Buy

Current Market Cap: $6.78B

See more insights into RYTM stock on TipRanks’ Stock Analysis page.